scholarly journals Responder identification in clinical trials with censored data

2006 ◽  
Vol 50 (5) ◽  
pp. 1338-1355 ◽  
Author(s):  
Victoria Kehl ◽  
Kurt Ulm
Keyword(s):  
Clinical Trials ◽  
Censored Data

Statistical inference on censored data for targeted clinical trials under enrichment design

2013 ◽  
Vol 12 (3) ◽  
pp. 165-173 ◽  
Author(s):  
Chen-Fang Chen ◽  
Jr-Rung Lin ◽  
Jen-Pei Liu
Keyword(s):  
Clinical Trials ◽  
Statistical Inference ◽  
Censored Data ◽  
Enrichment Design

Estimating and Comparing Reduction in HIV-1 RNA in Clinical Trials Using Methods for Interval Censored Data

2004 ◽  
Vol 35 (3) ◽  
pp. 286-292 ◽  
Author(s):  
Philippe Flandre ◽  
Alexandre Alcais ◽  
Diane Descamps ◽  
Laurence Morand-Joubert ◽  
V??ronique Joly
Keyword(s):  
Clinical Trials ◽  
Censored Data ◽  
Interval Censored Data ◽  
Interval Censored ◽  
Hiv 1

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

1973 ◽  
Vol 31 ◽  
pp. 404-405
Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Tumor Tissue ◽  
Soft Tissue Tumors ◽  
Clinical Usefulness ◽  
Electron Microscopic ◽  
Normal Cells ◽  
Electron Microscopic Autoradiography ◽  
Peritoneal Cells ◽  
Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I
Sign in / Sign up

Export Citation Format

Share Document